Facile generation of drug-like conformational antibodies specific for amyloid fibrils
- 29 April 2025
- journal article
- research article
- Published by Springer Nature in Nature Chemical Biology
- Vol. 21 (6) , 916-925
Abstract
Antibodies that recognize insoluble antigens, such as amyloid fibrils associated with neurodegenerative disorders, are important for research, diagnostic and therapeutic applications. However, these types of antibodies are difficult to generate, typically require animal immunization and also commonly require humanization in the case of therapeutic applications. Here we report a methodology for generating high-quality, fully human, conformation-specific antibodies against amyloid fibrils using a published human nonimmune library, yeast-surface display and quantitative fluorescence-activated cell sorting. Notably, this approach enables the isolation of conformation-specific antibodies against tau fibrils (Alzheimer’s disease) and α-synuclein fibrils (Parkinson’s disease) with combinations of high affinity, high conformational specificity and, in some cases, low off-target binding that rival or exceed those of clinical-stage antibodies specific for tau (zagotenemab) and α-synuclein (cinpanemab). This approach is expected to simplify the generation of conformation-specific antibodies against diverse protein aggregates and other insoluble antigens.Keywords
Funding Information
- National Institute on Aging (R01AG080016)
This publication has 52 references indexed in Scilit:
- Isolating Anti-amyloid Antibodies from Yeast-Displayed Libraries2022
- Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificityJournal of Biological Chemistry, 2021
- Sensitive detection of glucagon aggregation using amyloid fibril‐specific antibodiesBiotechnology and Bioengineering, 2019
- Soluble tau aggregates, not large fibrils, are the toxic species that display seeding and cross‐seeding behaviorProtein Science, 2018
- Transient Gene Expression in Suspension HEK293-EBNA1 Cells2018
- Pathological conformations involving the amino terminus of tau occur early in Alzheimer's disease and are differentially detected by monoclonal antibodiesNeurobiology of Disease, 2016
- Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer’s disease or corticobasal degeneration brainsActa Neuropathologica, 2014
- Dopamine‐induced α‐synuclein oligomers show self‐ and cross‐propagation propertiesProtein Science, 2014
- Single-domain antibodies recognize selectively small oligomeric forms of amyloid β, prevent Aβ-induced neurotoxicity and inhibit fibril formationMolecular Immunology, 2009
- Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tauJournal of Neuroscience Research, 1997